Trials / Unknown
UnknownNCT06118398
Efgartigimod in Acute Neuromyelitis Optica Spectrum Disorders
Effectiveness and Safety of Efgartigimod in the Acute Phase of Neuromyelitis Optica Spectrum Disorders-a Multicentric, Controlled, Retrospective, Real-Word Study
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 24 (estimated)
- Sponsor
- Feng Jinzhou · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to retrospective investigate the safety and effectiveness of Efgartigimod in the acute phase of neuromyelitis optica spectrum disorders (NMOSD) patients.
Detailed description
This is a multicentre, controlled, retrospective, real-world study which aims to compare the safety and effectiveness of Intravenous methylprednisolone (IVMP) with Efgartigimod injection add-on treatment with IVMP treatment in acute NMOSD patients. Twenty-four patients from 6 centres in China will be enrolled.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Intravenous methylprednisolone (IVMP) and Efgartigimod | IVMP 800-1000mg/day for 3-5 days plus Efgartigimod (Efgartigimod: 10mg/kg IV on Day 1, Day 8, Day 15 and Day 22 after IVMP.) |
| DRUG | IVMP | IVMP 800-1000mg/day for 3-5 days. |
Timeline
- Start date
- 2023-11-05
- Primary completion
- 2024-11-05
- Completion
- 2025-05-05
- First posted
- 2023-11-07
- Last updated
- 2023-11-07
Source: ClinicalTrials.gov record NCT06118398. Inclusion in this directory is not an endorsement.